Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CCR Translations

Is Cytomegalovirus a Therapeutic Target in Glioblastoma?

John H. Sampson and Duane A. Mitchell
John H. Sampson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duane A. Mitchell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-11-0992 Published July 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Several investigators have now demonstrated the expression of genes unique to cytomegalovirus (CMV) in malignant gliomas. Many of these genes promote oncogenesis, alter tumor microenvironment, and serve as immunologic targets. Is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes? Can CMV serve as a target for therapeutic intervention? Clin Cancer Res; 17(14); 4619–21. ©2011 AACR.

Commentary on Dziurzynski et al.,p. 4642

In this issue of Clinical Cancer Research, Dziurzynski and colleagues (1) report that CD133+ glioma stem cells (gCSC) express human CMV proteins and secrete CMV interleukin (IL)-10, a viral cytokine homolog of IL-10 that is capable of converting the widespread monocytes and microglia in glioblastomas (GBM) to an immunosuppressive tumor-supportive phenotype.

CMV is an endemic β-herpesvirus that does not usually cause significant clinical disease. However, CMV can cause fetal encephalitis and significant problems in immunocompromised adults. Herpesviruses have also been implicated in a number of human malignancies, including lymphoma, nasopharyngeal cancer, cervical cancer, and Kaposi sarcoma. Recent studies have reported the expression of proteins unique to CMV in a large proportion of malignant tumors, including colorectal carcinoma, prostate cancer, and gliomas (2, 3).

CMV induces numerous molecular changes within infected cells that could contribute to an oncogenic phenotype (3). For example, CMV has been shown to increase production of angiogenic factors, create a chronic inflammatory environment, and mediate numerous immunosuppressive changes in host cells. Furthermore, CMV-infected cells exhibit increased cellular motility and invasion, reduced p53 and retinoblastoma (Rb) function, elevated levels of telomerase, and increased resistance to chemotherapy-induced apoptosis. Although viral infection has not been shown to directly result in tumor formation, the CMV genome encodes several proteins that have been shown to possess direct transforming capability when stably expressed in normal cells.

Cobbs and colleagues (2) first identified CMV antigen expression in GBM. Using a series of optimized protocols, these authors showed the expression of CMV proteins (IE1, pp65, and late antigens) by immunohistochemistry in 27 out of 27 specimens, but not within surrounding normal brain or other brain pathology specimens. They detected CMV nucleic acids within these tumors using in situ hybridization and nested PCR confirmed by DNA sequencing. Our group (4) elaborated on this work and confirmed expression of IE1 and pp65 in >90% of GBM specimens by immunohistochemistry, detection of early and late viral proteins (IE1, pp65, and gB) in GBM primary cultures, and detection of nucleic acids using PCR (gB, pp65, and IE1) coupled with confirmatory DNA sequencing. Independent analyses by other groups (5, 6) also confirmed CMV antigen expression in these tumors, including the expression of US28, a viral gene that was recently implicated in tumorigenesis in a transgenic mouse model of colorectal cancer (7, 8).

Dziurzynski and colleagues (1) investigated whether CMV infection can contribute to the immunosuppressive microenvironment that is characteristic of GBM. Tumor-associated macrophages (TAM) exposed to factors such as IL-10 can acquire M2 properties that suppress immune responses and support proliferative ones, thereby enhancing malignant growth. Herein, Dziurzynski and colleagues demonstrate that TAMs derived from single-cell GBM digests express CMV antigens. Additionally, their examination of established CD133+ gCSCs revealed that CD133high gCSCs preferentially express CMV antigens and secrete viral IL-10. Thus, neural precursor cells, cells with self-renewal capacity, and monocytes are permissive to CMV infection and could function as reservoirs for CMV reactivation within these tumors. In vitro exposure of CD14+ monocytes to viral IL-10 downregulates expression of major histocompatibility complex (MHC) II and costimulatory molecule CD86, upregulates expression of the immune inhibitory molecule B7-H1, and increases intracellular TGF-β, VEGF, and phosphorylated STAT3. In return, viral IL-10–exposed monocytes increase gCSC migration. Therefore, in vivo exposure to viral IL-10 secreted by gCSCs could induce gCSC migration and an immunosuppressive milieu (Fig. 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

CMV in a GBM tumor microenvironment. Monocytes: Peripheral blood monocytes harboring latent or reactivated virus infiltrate malignant gliomas, where they differentiate into TAMs. Alternatively, gliomas that already harbor reactivated CMV infection may infect monocytes upon entry into the tumor microenvironment. GSCs enriched for CMV infection produce secreted viral IL-10 (vIL-10), which converts TAMs into an immunosuppressive and tumor-propagating phenotype. With regard to CMV in the tumor environment, subclinical CMV infection and expression of viral gene products may contribute to enhancing several of the tumorigenic properties of malignant glioma, including cellular migration and invasion, cellular proliferation, and resistance to cytotoxic therapy. Furthermore, the characteristic immunosuppressive phenotype in patients with GBM may be exacerbated by subclinical CMV infection within these tumors. Readily available antiviral agents may have therapeutic efficacy if viral propagation and gene expression are important for driving the malignant phenotype. Alternatively, immunotherapeutic targeting of CMV-associated tumors may leverage the presence of the virus within tumor cells to elicit specific killing whether the virus serves as a driver of tumor phenotype or merely as an opportunistic infection within the tumor microenvironment.

Although the presence of CMV in gliomas has been reported by several independent laboratories, other groups have reported a failure to detect the presence of CMV within these tumors (9, 10). This discrepancy is likely attributable to methodologic differences, as we and others have demonstrated that sensitive and optimized protocols are required to detect the very low levels of CMV likely present within these tumors. This observation raises the following questions: (i) is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes, and (ii) is CMV a clinically relevant target within these tumors for therapeutic intervention?

Koch's postulates are a stringent set of criteria that are used to determine whether an infectious agent causes a disease. However, these strict criteria are not often met in cases of virally induced cancers (11). The long latency between infection and cancer diagnosis, and the fact that only a small minority of individuals exposed to a cancer-promoting virus (i.e., human papillomavirus or hepatitis B) ever develop a malignancy associated with the viral infection, clearly implicates multiple factors in addition to the infectious insult in the oncogenic process. In the majority of cancers caused by viral infections, the viral DNA is present in very small copy number, usually less than 1 DNA copy per 10 tumor cells. Furthermore, it is now clear that chronic infections can facilitate oncogenesis through indirect mechanisms without coding for transforming genes themselves, such as Helicobacter pylori promotion of gastric cancer and gastric lymphoma, providing several mechanisms by which infections may promote cancer formation. Finally, microbial genomes within cancer cells are often altered such that viable infectious pathogens are not recoverable from tumor cells and thus fail to fulfill the major criteria for Koch's postulates. Future experiments that can demonstrate true modulation of the oncogenic phenotype via physiologic levels of infection with CMV-associated tumors will be pivotal for assessing any direct or indirect causality between CMV and oncogenesis.

The immunologic impact of CMV as reported by Dziurzynski and colleagues (1) raises a question: Would the levels of CMV viral IL-10 produced by in vivo gCSCs be sufficient to drive the immunosuppressive changes described within TAMs? If so, treatments targeting viral IL-10 could constitute novel and highly relevant therapeutic modalities. Similarly, evidence already exists that low levels of CMV viral gene expression may be sufficient for immunologic targeting (5), and it has also been demonstrated that killing by cytotoxic T lymphocytes can occur with presentation of as few as 3 antigenic peptides upon the surface of the target cell (12). Furthermore, if gCSCs do preferentially express CMV antigens in vivo, CMV-targeted therapies may profoundly inhibit malignant growth through eradication of this tumor-propagating population. The work of Dziurzynski and colleagues exemplifies that the continued characterization of biologically relevant levels of CMV infection as related to malignant progression and examination of CMV antigens as immune-mediated targets represent important and potentially promising areas of future research.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received May 4, 2011.
  • Accepted May 12, 2011.
  • ©2011 American Association for Cancer Research.

References

  1. 1.↵
    1. Dziurzynski K,
    2. Wei J,
    3. Qiao W,
    4. Hatiboglu MA,
    5. Kong LY,
    6. Wu A,
    7. et al.
    Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res 2011;17:4642–9.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cobbs CS,
    2. Harkins L,
    3. Samanta M,
    4. Gillespie GY,
    5. Bharara S,
    6. King PH,
    7. et al.
    Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62:3347–50.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Soroceanu L,
    2. Cobbs CS
    . Is HCMV a tumor promoter? Virus Res 2011;157:193–203.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Mitchell DA,
    2. Xie W,
    3. Schmittling R,
    4. Learn C,
    5. Friedman A,
    6. McLendon RE,
    7. et al.
    Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncol 2008;10:10–8.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Prins RM,
    2. Cloughesy TF,
    3. Liau LM
    . Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008;359:539–41.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Scheurer ME,
    2. Bondy ML,
    3. Aldape KD,
    4. Albrecht T,
    5. El-Zein R
    . Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008;116:79–86.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Bongers G,
    2. Maussang D,
    3. Muniz LR,
    4. Noriega VM,
    5. Fraile-Ramos A,
    6. Barker N,
    7. et al.
    The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 2010;120:3969–78.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Slinger E,
    2. Maussang D,
    3. Schreiber A,
    4. Siderius M,
    5. Rahbar A,
    6. Fraile-Ramos A,
    7. et al.
    HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 2010;3:ra58.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Lau SK,
    2. Chen YY,
    3. Chen WG,
    4. Diamond DJ,
    5. Mamelak AN,
    6. Zaia JA,
    7. et al.
    Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 2005;18:838–43.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Duncan CG,
    2. Leary RJ,
    3. Lin JC,
    4. Cummins J,
    5. Di C,
    6. Schaefer CF,
    7. et al.
    Identification of microbial DNA in human cancer. BMC Med Genomics 2009;2:22.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Zur Hausen H
    . The search for infectious causes of human cancers: where and why. Virology 2009;392:1–10.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Purbhoo MA,
    2. Irvine DJ,
    3. Huppa JB,
    4. Davis MM
    . T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol 2004;5:524–30.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 17 (14)
July 2011
Volume 17, Issue 14
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Is Cytomegalovirus a Therapeutic Target in Glioblastoma?
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is Cytomegalovirus a Therapeutic Target in Glioblastoma?
John H. Sampson and Duane A. Mitchell
Clin Cancer Res July 15 2011 (17) (14) 4619-4621; DOI: 10.1158/1078-0432.CCR-11-0992

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Is Cytomegalovirus a Therapeutic Target in Glioblastoma?
John H. Sampson and Duane A. Mitchell
Clin Cancer Res July 15 2011 (17) (14) 4619-4621; DOI: 10.1158/1078-0432.CCR-11-0992
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • FLASH-RT for GBM: Think Fast
  • Antibody Peptides as Vaccine in CLL
  • Ipi-nivo in Sarcomatoid RCC
Show more CCR Translations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement